RESPONSE PREDICTION IN METASTATIC RENAL CELL CARCINOMA TREATED WITH ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TARGETED THERAPY AND/OR IMMUNE CHECKPOINT INHIBITORS KU Leuven
In recent years, major improvements have been achieved in the treatment of metastatic clear-cell renal cell carcinoma with the introduction of angiogenesis-inhibitors and immune therapy. Despite highly variable patient responses, no markers for patient treatment selection have entered the clinic thus far. We aim to search for predictive biomarkers in order to select the right patient for the right therapy. This will allow us to obtain better ...